アステラス製薬

We are excited to announce that Ciconia Bioventures Inc. (Ciconia) has been established as a joint venture company for incubation of early drug discovery programs in Japan based on a master agreement on April 22, 2024, signed among Takeda, Astellas, and Sumitomo Mitsui Banking Corporation – SMBC Group. Ciconia seamlessly covers the entire process from early drug discovery research to establishment of biotech startups, with the aim of translating innovative technologies and drug discovery programs originating in Japan into clinical applications. Astellas highly expect that Ciconia will activate Japan’s drug discovery ecosystem in collaboration with a wide variety of players from industry, government, and academia, and deliver innovative therapeutics to patients around the world through its global expansion. We will provide multifaceted support to Ciconia based on our drug discovery and business expertise, and networks we have cultivated worldwide. Read more:  https://lnkd.in/gimZXK6a #DrugDiscovery #innovation #collaboration

Today, the entire Astellas team is recognizing #WorldSightDay, reaffirming our commitment to advancing innovation for the hundreds of millions of people globally living with vision loss. We understand that vision loss is deeply personal, and what we each value most through sight is unique. That’s why we’ve launched a competition within our teams globally asking them to answer the simple question: “What’s your favorite sight?” Through this, we aim to reflect on and share the precious moments our eyes capture – moments we strive to preserve for our patients.  We’re dedicated to building a future where eye diseases that cause blindness are treatable and, ultimately, preventable. Watch the video to learn about the impact of these diseases and why this mission is so critical to us.  #Ophthalmology #RetinalDisease #ChangingTomorrow

We’re proud to share that today, Astellas announced an exclusive option and license agreement with AviadoBio for AVB-101, an investigational, AAV-based #GeneTherapy in Phase 1/2 development for patients with frontotemporal #dementia with progranulin mutations (FTD-GRN). This partnership further supports our commitment to deliver transformative value for patients and we look forward to working with AviadoBio to help support the unmet need for treatment options for this neurodegenerative disease. Learn more here:  https://lnkd.in/gbeZGFRz

We are proud to have completed our first product #donation in partnership with Direct Relief . We have donated 2,000 boxes of immunosuppressive therapy in Tanzania. This donation aligns with our #AccessToMedicines Strategy to improve access to medicines throughout the product lifecycle. This milestone is significant as we continue to explore ways to expand access to medicines, helping to improve the lives of patients worldwide in an equitable and sustainable manner. Read more: https://bit.ly/4evWhV7 #sustainability

We are happy to announce that our Integrated Report 2024 is now available. This report highlights our progress in implementing the Corporate Strategic Plan 2021, while also conveying how we create and deliver VALUE for the mid- and long-term future. This year, we have disclosed Astellas’ logic tree to show how our financial and non-financial initiatives will enhance its enterprise value. You can also find many passionate interviews with our Top Management, outside Directors, and employees. Click on the link below to learn more about Astellas and its exciting future. https://bit.ly/3NbVOv7 #IntegratedReport2024

In pioneering fields such as #CellandGeneTherapy, cross-industry collaboration and communication are essential for accelerating the delivery of potential transformative medicines to patients. At the upcoming Cell and Gene Meeting on the Mesa, October 7-9, Astellas speakers will be setting out our vision in cell and gene therapy, exploring how to navigate the evolving gene therapy landscape in Asia, and sharing updates on our work in diseases facing significant unmet medical needs, such as Friedreich ataxia (#FA). Our partnering teams will also be onsite, looking for like-minded innovators committed to bringing ground-breaking therapies to patients, faster. Get in touch if you’re attending: https://lnkd.in/gapkuMAZ #ScienceFirstForPatients #ChangingTomorrow #CGMesa24

Over the past decade, Astellas has transformed from an #oncology newcomer to a recognized leader, with three best-in-class cancer therapies prescribed to over one million patients across 70 countries to date. This remarkable journey has been fueled by relentless innovation and a commitment to addressing high unmet needs in #CancerTreatment. In our latest article on Our Stories, Chief Medical Officer Tadaaki Taniguchi shares his insights on how Astellas is advancing an early-stage pipeline of novel modalities, including immuno-oncology and targeted protein degradation. These cutting-edge approaches target difficult-to-treat cancers and can potentially have transformative impact on the lives of those battling the disease. Read the full story on our corporate website:  https://lnkd.in/gXZJuwTv

We're excited to announce that Nick Eshkenazi, our Chief Digital & Transformation Officer (CDTO), has been named CDTO of the Year in Pharmaceutical Manufacturing by C-Suite Insider. This recognition reflects Nick's leadership in advancing Astellas' digital and transformation agenda, driving innovation, and fostering collaboration across the organization. Thank you to C-Suite Insider for this incredible recognition. We are proud to have Nick leading the charge in shaping the future of digital transformation at Astellas. Read more about the award:  https://lnkd.in/gYk2MJMy #DigitalTransformation #innovation #leadership

During a recent trip to Europe, our CEO, Naoki Okamura and CCO, Claus Zieler, had the privilege of visiting two world-renowned research centers in Paris: the Institut de la Vision and Gustave Roussy. Both institutions are at the forefront of medical innovation and exemplify the power of collaboration in advancing healthcare beyond national boundaries. At the Institut de la Vision, senior leaders from Astellas were given an overview of their pioneering research work in gene therapy, artificial vision, and cell therapy. These cutting-edge approaches are bringing new hope to patients who are waiting with retinal degeneration and optic neuropathy. The groundbreaking artificial vision systems and stem cell therapies are transforming what is possible in restoring sight. Astellas colleagues were impressed by the collaborative spirit among researchers and healthcare professionals at the Institute that really fosters an environment that accelerates innovation to ensure these advancements can be delivered to more patients quickly. During the same trip, the team were also guests of Professor fabrice andre Head of Research, Fabrice Barlesi, CEO at Gustave Roussy, and Professor Eric Vivier President of Paris Saclay Cancer Cluster (PSCC), renowned for its incredible advancements in oncology research. As a global leader in cancer care, their expertise in immunotherapy, personalized medicine, and precision oncology is unparalleled. Andrew Mortlock, Head of Early Development and Alan McDougall, Head of Medical Affairs in Europe were especially interested to learn about potential opportunities for joint research initiatives in developing next-generation immuno-oncology therapies. By leveraging the expertise of research and academic institutions is central to enhancing the Astellas oncology portfolio and accelerating the development of transformative treatments. With France recently celebrating a successful Olympic games—following previous hosts, Japan—the leaders enjoyed meeting our talented French team at the Astellas office to share their experiences. The French culture, with its emphasis on empathy and holistic care, aligns perfectly with the core Astellas value of focusing on patient needs. General Manager of France, Ghislaine Leleu and Regional President, Damien Bailly gave numerous examples of this commitment of putting patients first and it was evident in every discussion and initiative the team presented. During the panel discussion, the French team’s dedication to understanding and addressing patient needs was clearly evident, as many examples showed how their efforts to deliver innovative solutions make a meaningful difference to patients’ lives.

“I am very proud of you. I love the fact that every team functions as a team. Especially in the Brand Teams, the amount of collaboration, responsibility and accountability perfectly matches my definition of our agile ways of working.”    Naoki Okamura shared this with the team at the end of his visit to Astellas Pharma in Germany. The CEO was accompanied by Claus Zieler, Damien Bailly and Alan McDougall. The combined global and regional management team was able to get an appreciation of the cultural transformation taking shape in Germany, while German colleagues had the opportunity to learn more about our global strategy and spend quality time with senior leaders, face-to-face.    In addition to presentations and discussions, the German team hosted a town hall in a ‘talk show’ format, with the local management team partnering with their respective colleagues in a highly engaging way. Above all, the senior leaders dedicated significant time to individual and small group conversations with colleagues from the German affiliate on numerous occasions during the two day visit, such as over informal employee lunches.     Naoki Okamura and Claus Zieler also visited the Bavarian State Ministry of Health (Bayerisches Staatsministerium für Gesundheit, Pflege und Prävention) together with Dr. Galin Michailov and Dr. Stefanie Schuster. During the visit, Claus Zieler emphasized that Astellas, as a research-based pharmaceutical company, needs reliable framework conditions, such as a supportive regulatory environment, stable funding for innovation and incentives for R&D. He added that Germany could do much more to increase its attractiveness compared with other countries.    Claus Zieler paid tribute to the dedication and passion of the German team at the end of the visit, telling colleagues: “I leave Germany deeply impressed by what you have accomplished, and I really like the energy that I saw during my visit, as well as the cross-functional ways of working and alignment to our common goal of bringing innovative products to patients. I would like to especially point out that the Brand Teams are very integrated teams in their mindset, ways of working and execution.”